{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-252207","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.620865+00:00","generated_at":"2026-05-17T01:55:32.000398+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alkermes Q3 revenue $394.2M, GAAP EPS $0.49; raises FY2025 guidance","bullets":["Q3 total revenues $394.2M up 4% YoY; proprietary net sales $317.4M up 16% YoY.","LYBALVI sales $98.2M (+32% YoY); ARISTADA $98.1M (+16% YoY); VIVITROL $121.1M (+7% YoY).","GAAP net income $82.8M vs $92.4M in Q3 2024; diluted EPS $0.49.","FY2025 revenue guidance raised to $1.43-1.49B from $1.34-1.43B; GAAP net income now $230-250M.","CEO highlighted proposed Avadel acquisition and positive phase 2 data for alixorexton in narcolepsy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-252207","json":"https://secwatch.observer/filing/0001193125-25-252207.json","markdown":"https://secwatch.observer/filing/0001193125-25-252207.md","text":"https://secwatch.observer/filing/0001193125-25-252207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000119312525252207/0001193125-25-252207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000119312525252207/alks-20251028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:55:32.000398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}